Targets › MMP2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.
Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. (UniProt, P08253)
Open in Phaseline: the race on MMP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes CAR-T cell therapy with chlorotoxin tumor-targeting domain recognizing MMP2 | MMP2 | Phase 1 | Recurrent Glioblastoma | May 2027 |
Recurrent Glioblastoma (1)
other (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.